Thanks to a White Knight, Bill Ackman’s Allergan activist campaign ends with $2.5 billion profit

January 19th, 2015
| More
Is it really an honest day of work, when your hedge fund rakes in a $2.5 billion dollar profit, on an investment bet that gained on average $12 million dollars a day? That is a question posed to activist hedge fund manager Bill Ackman, of the Pershing Square Capital hedge fund who tried to partner with Valeant Pharmaceuticals to takeover Allergan PLC, the producer of Botox.

Never mind Ackman’s attempts to purchase Allergan were turned down numerous times. According to the New York Post, Ackman took it upon himself to fly around the country to stir up the shareholders, persuading them to abandon most of their board members.

In the end, drugmaker Actavis swooped in as a White Knight to purchase Allergan for $66 billion, helping Allergan evade Valeant, but still netting Pershing Square the most profitable gain ever from a activist bet.

Notably, Pershing Square is currently ranked #2 spot on the Top 75 Healthcare and Biotech Hedge Fund list, while also holding the #3 spot on the Top Activist Hedge Fund list
For Detailed Investor Profiles on these Investors, click below:
Pershing Square Capital Management
Related People: Nicholas Botta; Roy J. Katzovicz; Scott Ferguson*; William 'Bill' Ackman
Related Entities: Leucadia Corporation (NYSE: LUK); Pershing Square Capital; Pershing Square IV; Pershing Square LP
Related Article Tags: Shareholder Activists, Corporate Raiders and Proxy Battles; Investment Management and Hedge Fund Firm Mergers, Acquisitions, Spin-offs and Transactions

More Recent Headlines

Top Activist Hedge Funds close in on $200 billion mark; ValueAct Capital, Elliott Management & JANA Partners lead the way

Chicago and Texas hedge funds dominate the Top Central U.S. Hedge Fund List

Trian’s Nelson Peltz wants to squeeze some nutrition, health, and profits out of DuPont

Mid-Sized Hedge Funds Batten down the Hatches, Squeak out a 0.5% Gain

Bill Ackman's Pershing Square Foundation donates $10M to TheDream.US

Top Emerging Hedge Fund Managers up 30%; Corvex, Pointstate, & Soroban claim Top Spots

Jeff Smith’s Starboard Value Wins – No More Free Breadsticks at Olive Garden

JANA Partners’ activist campaign with Civeo ends abrubtly on New Year’s Eve

Pershing Square’s Bill Ackman, Glenview’s Larry Robbins, & Third Point’s Dan Loeb have a stellar 2014

Steve Cohen’s Point72 announces Rubric Capital with David Rosen at the helm